Based on this, a phase I/IIa clinical trial assessing the safety of GDNF-overexpressing human stem cells committed to astrocyte transplantation in the lumbar spinal cord of ALS patients was later activated (NCT02943850). The gene discussed is GDNF; the disease is amyotrophic lateral sclerosis.